Humacyte, Inc.

A significant holder filed an amended Schedule 13D on Humacyte, Inc. (HUMA) on June 15, 2026. Body unavailable — excerpt contains only the SEC cover-page header without filer name, updated stake, or amended intent.

Humacyte, Inc. entered into an underwriting agreement on June 10, 2026, with Barclays, BTIG, and Titan Partners for an underwritten public offering of 47,619,048 shares of common stock at $1.05 per share ($50.0M gross). Net proceeds after $3.0M underwriting discount were approximately $47.0M before expenses; the underwriters received a 30-day option to purchase up to an additional 7,142,857 shares. Delivery was expected on or about June 12, 2026. This is a highly dilutive offering for a small-cap clinical-stage biotech (shares priced near 52-week lows), raising capital to fund continued vascular implant product commercialization.

Humacyte, Inc. filed the 424B5 prospectus supplement on June 10, 2026, for its underwritten public offering of 47,619,048 shares at $1.05 per share (total $50,000,000 gross; net ~$47,000,000 after underwriting discounts). An overallotment option covers up to 7,142,857 additional shares. The prior-day closing price was $1.39, meaning the offering was priced at a ~24% discount to the last reported sale price. Proceeds will fund operating expenses and working capital. The offering is materially dilutive at current share price levels, signaling the company needs external capital to sustain operations.

Humacyte, Inc. filed a preliminary prospectus supplement (424B5) to offer shares of common stock under its existing shelf (Reg. No. 333-290231), with share count, price, and total proceeds left blank pending final pricing. The stock was priced at $1.39 as of June 9, 2026; joint book-runners are Barclays, BTIG, and Titan Partners. As a smaller reporting company with disclosed going-concern language in its base prospectus, this is a dilutive equity offering whose full size is not yet set.

Humacyte, Inc. held its 2026 Annual Meeting on June 9, 2026, with 222,019,108 shares outstanding as of the April 23 record date. Stockholders approved an amendment to the Certificate of Incorporation increasing authorized common stock from 350,000,000 to 550,000,000 shares (a 200 million share increase), effective June 9, 2026 upon Delaware filing. Additional proposals were voted on but vote results are truncated in the excerpt. The authorized share increase is potentially dilutive and provides substantial new headroom for future equity raises or compensation programs.

Humacyte (HUMA) received a Nasdaq Staff Deficiency Letter notifying the company that its Class A common stock had traded below $1.00 per share for 30 consecutive business days ending May 1, 2026, triggering Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. Failure to regain compliance could result in delisting proceedings.

Fresenius Medical Care AG & Co. KGaA (Germany) filed an amended Schedule 13D/A reporting an 8.4% beneficial ownership stake in Humacyte (HUMA), representing 18,312,735 shares held with shared voting and dispositive power. Fresenius is Humacyte's commercial distribution partner for its acellular tissue-engineered vessel products in markets outside the United States, and its ownership stake reflects that strategic relationship.

Humacyte (HUMA) entered into the Third Amendment to its Distribution Agreement with Fresenius Medical Care on April 21, 2026, covering distribution of Humacyte's 6mm acellular tissue-engineered vessel (ATEV) for vascular access indications outside the United States. The amendment updates the terms of the existing commercial partnership. A press release was also filed under Regulation FD (Item 7.01) announcing the amendment.